Journal of Diabetes Science and Technology 2008; 2(1):47-57.
Journal of Diabetes Science and Technology 2008; 2(2):205-212.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.
This press release contains forward-looking statements, including
statements related to the positioning of Technosphere Insulin and
differentiating it from other insulins. Words such as "believes",
"anticipates", "plans", "expects", "intend", "will", "goal", "potential"
and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon MannKind's
current expectations and involve risks and uncertainties. Actual results
and the timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to the
progress, timing and results of clinical trials, whether results of further
clinical trials of Technosphere(R) Insulin will show efficacy and safety
|SOURCE MannKind Corporation|
Copyright©2008 PR Newswire.
All rights reserved